Prevention of Deep Vein Thrombosis following Total Hip Replacement by Low Molecular Weight Heparinoid

Summary

We assessed the safety and efficacy of the novel low molecular weight heparinoid Lomoparan (Org 10172) for the prevention of deep-vein thrombosis in patients undergoing elective total hip replacement in a randomized, placebo-controlled, double-blind trial in 197 consecutive patients. The heparinoid (750 anti-factor Xa-units, s. c., b.i.d.) was administered to 97 patients and 99 patients received placebo. Study medication was started preoperatively and continued for 10 days. Efficacy was assessed by bilateral phlebography at day 10, postoperatively.

The incidence of deep-vein thrombosis was 56.6% and 15.5% respectively in the placebo and heparinoid treated patients (incidence reduction: 74%; P <0.001). This reduction was observed both for proximal-vein thrombosis (25% to 8%; P <0.005) and isolated calf-vein thrombosis (31% to 7%; P <0001.

No major hemorrhage was observed. The number of red-cell units transfused and drain-fluid loss were comparable for the two study groups. Six patients in the heparinoid group and none in the control group developed minor wound hematomas (P <0.05).

During an 8-week post-discharge follow-up period three patients with a normal venogram at day 10 developed clinically apparent venous thromboembolism, which was confirmed by objective testing. All three patients belonged to the heparinoid-treated group.

We conclude that 750 anti-factor Xa units Org 10172 s.c. twice daily starting preoperatively is safe and effectively reduces early deep-vein thrombosis following elective total hip replacement. Further studies on the incidence of post-discharge thromboembolism are required.

• References

• 1 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-1173
• 2 Salzman EW, Hirsh J. Prevention of venous thromboembolism. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd ed.. JB Lippincott Co.; Philadelphia, PA: 1987. pp 1252-1265
• 3 Stamatakis JD, Kakkar W, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. Br Med J 1977; 2: 223-225
• 4 Bergqvist D. Prevention of postoperative deep vein thrombosis in Sweden. Results of a survey. World J Surg 1980; 4: 489-495
• 5 The Office of Medical Application of Research, National Institutes of Health Prevention of venous thrombosis and pulmonary embolism; consensus conference. JAMA 1986; 256: 744-749
• 6 Ten Cate H, Henny CP, ten Cate JW, Biiller HR. Clinical studies with low molecular weight heparin(oid)s: An interim analysis. Am J Hematol 1988; 27: 146-153
• 7 The European Fraxiparin Study Group Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-1063
• 8 Kakkar VV, Murray WJG. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-791
• 9 Turpie AGG, Levine MN, Hirsh J, Carter CC, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of low molecular weight heparin to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 10 Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988; 60 (03) 407-410
• 11 Eriksson BI, Kàlebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991; 73A: 484-493
• 12 Levine MN, Hirsh J, Gent M, Turpie AGG, Leclerc J, Powers PJ, Jay RM, Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med 1991; 114: 545-551
• 13 Meuleman DG, Hobbelen PM, van Dedem G, Moelker HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-363
• 14 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 15 Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I, Mcbride J. The value of adding impedance plethysmography to ¹²⁵I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: a comparative study between patients undergoing general surgery and hip replacement. Thromb Res 1979; 15: 227-234
• 16 Ten Cate H, Lamping RJ, Henny ChP, Prins A, ten Cate JW. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30: 860-864
• 17 Dukes GE, Sanders SW, Russo J, Sewnson E, Burnakis TG, Saffle JR, Warden GD. Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 1984; 100: 646-650
• 18 Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed.. John Wiley; New York: 1981. pp 19-27
• 19 Morris GK. Prevention of venous thromboembolism; a survey of methods used in general and orthopedic surgery. Lancet 1980; I: 572-574
• 20 Gent M, Roberts RS. A meta-analysis of studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest 1986; Suppl (89) 396-400
• 21 Bergqvist D. Oral anticoagulants for prophylaxis against postoperative thromboembolism. Acta Chir Scand 1988; Suppl (543) 43-47